Status:
COMPLETED
Efficacy of Lu 31-130 in Patients With Schizophrenia
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The main purpose with the study is to evaluate the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to placebo.
Detailed Description
Schizophrenia is a serious and disabling mental disorder that affects approximately 1% of the world's population. Antipsychotic drugs remain the cornerstone in the pharmacotherapy of schizophrenia. Ho...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- The patient has a primary diagnosis of schizophrenia
- The patient experiences clinically significant symptoms
- The patient did not experience an acute exacerbation requiring hospitalisation within the last 6 months
- The patient's medication has been stable for at least 4 weeks prior screening
- The subject has normal serum values of parameters associated with liver function
Exclusion
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT00768326
Start Date
March 1 2007
End Date
November 1 2009
Last Update
November 8 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
DE001
Munich, Germany, 80336